<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3B5C8E6A-D92C-4351-B022-EBE6FA81514D"><gtr:id>3B5C8E6A-D92C-4351-B022-EBE6FA81514D</gtr:id><gtr:name>Upstate Medical University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3B5C8E6A-D92C-4351-B022-EBE6FA81514D"><gtr:id>3B5C8E6A-D92C-4351-B022-EBE6FA81514D</gtr:id><gtr:name>Upstate Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A56659BA-683E-45AE-AB1C-DA0690F1DA7D"><gtr:id>A56659BA-683E-45AE-AB1C-DA0690F1DA7D</gtr:id><gtr:firstName>Awen</gtr:firstName><gtr:surname>Gallimore</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801190"><gtr:id>B567AA75-ACC1-494F-A0FB-4E91B993039A</gtr:id><gtr:title>Characterisation of Positive and Negative Influences in Tumour Immunity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801190</gtr:grantReference><gtr:abstractText>The main function of our white cells is to eliminate infectious agents such as bacteria and viruses. These cells form part of the immune system and their activation is known as an immune response. Certain types of white cells, known as regulatory T cells, are believed to dampen down immune responses that are considered harmful ?these may be immune responses directed towards normal, uninfected tissues. Since tumours arise from normal tissues, it was considered possible that these regulatory T cells inhibit immune responses to tumours. Several laboratories have shown that the cells do indeed inhibit immune responses to tumours, responses that could otherwise promote tumour destruction. 
 A two-pronged approach is now warranted to find out how this information can be harnessed for the purposes of treating people with cancer. Firstly, the immune responses capable of promoting tumour destruction must be identified and secondly the precise way in which regulatory T cells act to stop these responses working effectively must be discovered. This approach will allow us to determine how the immune system can be manipulated for the treatment of a wide variety of cancers, including breast cancer, lung cancer, ovarian cancer and colorectal cancer.</gtr:abstractText><gtr:technicalSummary>Many fundamental questions remain unanswered in the field of tumour immunology. The type of immune effector cells / molecules capable of controlling tumour growth in vivo have not yet been definitively identified. In addition, whilst many pathways of tumour-induced immunosuppression are thought to contribute to the overall paucity of anti-tumour immunity, these pathways remain poorly characterised. A resurgence of interest in T cell mediated tolerance has revealed that a subpopulation of T cells, named regulatory T cells (Tregs) may play a key role in inhibiting effective anti-tumour immunity. These Tregs, identified by expression of the CD4 antigen and the forkhead transcription factor, Foxp3, keep innate and adaptive immune responses in check; suppress responses to self- and non-self antigens and impinge on almost all aspects of immune activity including transplantation, allergy, infection, autoimmunity and tumour immunity. A clear objective of Treg research is to determine how they can be manipulated therapeutically to treat a wide range of immune-based diseases. 
Cancer is a disease where manipulation of Treg activity has obvious therapeutic potential. An enormous body of work indicates that overall, Tregs are present at an increased frequency in the peripheral blood lymphocytes (PBL) of patients with cancer compared to healthy controls. Depletion of Tregs from PBL in vitro, uncovers T cell responses to tumour antigens and, in vivo, depletion of Tregs can enhance immune responses generated following vaccination. Furthermore, several reports indicate that high frequencies of Tregs correlate with more advanced disease implying that Tregs facilitate progression of cancer. I hypothesize that tumour development can be prevented or controlled at an early stage by effective immune responses. However, these responses are suppressed by Tregs. The identification of immune mechanisms of tumour control and an understanding of how Tregs impinge on these will enable therapeutic strategies to be developed for the successful treatment of patients with cancer. Detailed investigations into both issues will be undertaken. Specifically, the study aims to identify the effector cells/molecules that participate in controlling tumour growth in vivo and to assess the consequences of this immune activity on the fate of the tumour. In addition, an investigation of Treg activity in tumours will be performed. The overall aim of this two-pronged approach, which involves evaluating both positive and negative influences on tumour immunity, is to inform the design of more effective therapeutic immune interventions for patients with cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2012-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>476808</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Upstate Medical University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Induction of HEV in tumours</gtr:description><gtr:id>0F2A6C5E-5D16-46B9-A887-8F2F52ABA71C</gtr:id><gtr:impact>T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.
Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, Cutting S, Ladell K, Wynn KK, Withers D, Price DA, Ager A, Godkin AJ, Gallimore AM.
Cancer Res. 2012 Nov 1;72(21):5473-82.

Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of na&amp;iuml;ve CD4+ T cells via blood vessels and lymphatics.
Ondondo B, Jones E, Hindley J, Cutting S, Smart K, Bridgeman H, Matthews KK, Ladell K, Price DA, Jackson DG, Godkin A, Ager A, Gallimore A.
Int J Cancer. 2014 May 1;134(9):2156-67.</gtr:impact><gtr:partnerContribution>Ann Ager is an expert in T cell trafficking thus her expertise has been pivotal to driving our research forward</gtr:partnerContribution><gtr:piContribution>Identified that regulatory T cells inhibit generation of HEV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University School of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Infection and Immunity</gtr:department><gtr:description>Analysis of clonal expansion in tumours</gtr:description><gtr:id>17305A3C-4DB1-4D62-9215-440F24527130</gtr:id><gtr:impact>Paper in Cancer Research</gtr:impact><gtr:partnerContribution>Sorting highly purified T cell populations, use of 18-colour flow cytometry, RACE-PCR for T cell receptor analyses</gtr:partnerContribution><gtr:piContribution>Generated model whereby tumour-infiltrating T cells can be isolated and characterised.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Immunology and Inflammation</gtr:department><gtr:description>T cell receptor analysis</gtr:description><gtr:id>D107FA14-EDCB-4E1B-AB85-6C10F4113C74</gtr:id><gtr:impact>Publication in Cancer Research</gtr:impact><gtr:partnerContribution>Established methods for analysis of T cell receptor repertoires</gtr:partnerContribution><gtr:piContribution>We have generated a tumour model whereby the relationship between regulatory and conventional T cells can be characterised.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University School of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Infection and Immunity</gtr:department><gtr:description>Induction of HEV in tumours</gtr:description><gtr:id>AEA3A954-A4BF-405D-9470-92F012D76EE7</gtr:id><gtr:impact>T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.
Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, Cutting S, Ladell K, Wynn KK, Withers D, Price DA, Ager A, Godkin AJ, Gallimore AM.
Cancer Res. 2012 Nov 1;72(21):5473-82.

Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of na&amp;iuml;ve CD4+ T cells via blood vessels and lymphatics.
Ondondo B, Jones E, Hindley J, Cutting S, Smart K, Bridgeman H, Matthews KK, Ladell K, Price DA, Jackson DG, Godkin A, Ager A, Gallimore A.
Int J Cancer. 2014 May 1;134(9):2156-67.</gtr:impact><gtr:partnerContribution>Ann Ager is an expert in T cell trafficking thus her expertise has been pivotal to driving our research forward</gtr:partnerContribution><gtr:piContribution>Identified that regulatory T cells inhibit generation of HEV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8DDD4ADB-3870-456C-85A1-BBD5C5161AB9</gtr:id><gtr:impact>Results of the activity cannot yet be established.

It is too soon to determine whether there are any notable impacts.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Animal Workers: Cardiff University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6C8CB40E-96ED-42CA-B0AF-A2533DD0617F</gtr:id><gtr:impact>10 animal workers attended the talk and asked questions regarding the research both in relation in animal health and welfare and the science and its implications for advances in medicine

The audience were very pleased to improve their understanding of work in which they participate directly.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Cancer Research Wales</gtr:fundingOrg><gtr:id>DD3F602A-46BA-4244-8005-1F5918EBECF4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>84300</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Cancer Research Wales</gtr:fundingOrg><gtr:id>098E1C9E-F50B-40CA-B65B-13D1BEE11CDF</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>EF50BA16-ED43-438E-8B4D-E8FDE6A511AB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>313321</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>3EB7665F-DFF0-4F12-AFDA-E0DB626AFF2D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2021-08-02</gtr:end><gtr:fundingOrg>Cancer Research Wales</gtr:fundingOrg><gtr:id>473825E3-B8C9-4662-8257-33300740AB71</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>GW4</gtr:fundingOrg><gtr:id>7D814797-1632-4147-AD55-6E6A358DD186</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The intervention was a pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX&amp;reg;) vaccination in patients with inoperable metastatic colorectal cancer.
In this randomised, open-label, phase 2 clinical trial, TaCTiCC (TroVax&amp;reg; and Cyclophosphamide Treatment in Colorectal Cancer), we recruited patients with inoperable, metastatic CRC, with prior stable or responding disease following 12 weeks standard chemotherapy. Patients were centrally randomised to receive either no treatment (watch &amp;amp; wait unless clinically indicated; Group 1), metronomic oral 50mg B.D. CPM on treatment weeks 1 &amp;amp; 3 (Group 2), intramuscular injections of 1x109 TCID50 TroVax&amp;reg; on treatment weeks 4, 6, 8, 10, 12 and 16 (Group 3), or a combination of the two treatments (Group 4). The primary endpoint was the magnitude of anti-5T4 immune responses generated at treatment week 7, as determined by the presence of 5T4-specific T cell responses by IFN-? ELISPOT and 5T4 antibodies by ELISA. Secondary endpoints included analysing the kinetics of anti-5T4 responses, progression-free survival (PFS) and overall survival (OS). This trial is registered with EudraCT (2010-024380-41) and the ISRCTN registry</gtr:description><gtr:id>6E239968-F889-4BBC-B528-843E57D21086</gtr:id><gtr:impact>Prior depletion of Tregs by CPM does not boost immune responses generated to TroVax&amp;reg; vaccination, however, both CPM and TroVax&amp;reg; independently induced beneficial anti-tumour immune responses resulting in prolonged survival of end-stage CRC patients without toxicity. These data warrant further investigation of the two treatments in separate, larger clinical trials.Funding applications are underway.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>CLINICAL TRIAL - TACTICC</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4BA7EDE-AF64-48AB-991D-BFEF3AE06847"><gtr:id>E4BA7EDE-AF64-48AB-991D-BFEF3AE06847</gtr:id><gtr:title>Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of na&amp;iuml;ve CD4+ T cells via blood vessels and lymphatics.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85589C5C-EC58-40BA-9C3D-F8C09F18A07A"><gtr:id>85589C5C-EC58-40BA-9C3D-F8C09F18A07A</gtr:id><gtr:title>Suppression of tumour-specific CD4? T cells by regulatory T cells is associated with progression of human colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e91fffe206cb1e737057bda6fec65cc"><gtr:id>8e91fffe206cb1e737057bda6fec65cc</gtr:id><gtr:otherNames>Betts G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/486D83E6-0955-4674-9B61-5794A920B191"><gtr:id>486D83E6-0955-4674-9B61-5794A920B191</gtr:id><gtr:title>T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/246d843e37510a3a54f0e2764657203b"><gtr:id>246d843e37510a3a54f0e2764657203b</gtr:id><gtr:otherNames>Hindley JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70708E00-1845-4F48-9BB0-ADE5A0D1DDC1"><gtr:id>70708E00-1845-4F48-9BB0-ADE5A0D1DDC1</gtr:id><gtr:title>Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/246d843e37510a3a54f0e2764657203b"><gtr:id>246d843e37510a3a54f0e2764657203b</gtr:id><gtr:otherNames>Hindley JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF92B386-7C0D-47EA-AD52-3B1812F9DE93"><gtr:id>EF92B386-7C0D-47EA-AD52-3B1812F9DE93</gtr:id><gtr:title>Suppression of tumour-specific CD4? T cells by regulatory T cells is associated with progression of human colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e91fffe206cb1e737057bda6fec65cc"><gtr:id>8e91fffe206cb1e737057bda6fec65cc</gtr:id><gtr:otherNames>Betts G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4368482A-2006-4940-ACE2-5A962810DA37"><gtr:id>4368482A-2006-4940-ACE2-5A962810DA37</gtr:id><gtr:title>A distinct chemokine axis does not account for enrichment of Foxp3(+) &amp;nbsp;CD4(+) T cells in carcinogen-induced fibrosarcomas.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70EB1A19-51A3-43BB-8CB1-AA4E7A50ADA2"><gtr:id>70EB1A19-51A3-43BB-8CB1-AA4E7A50ADA2</gtr:id><gtr:title>Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/192c5070f73bd27c5e7e91060c31e213"><gtr:id>192c5070f73bd27c5e7e91060c31e213</gtr:id><gtr:otherNames>Scurr MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6617EF4C-69FA-4C5F-8225-A564722B9B24"><gtr:id>6617EF4C-69FA-4C5F-8225-A564722B9B24</gtr:id><gtr:title>Home sweet home: the tumor microenvironment as a haven for regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801190</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>